| Literature DB >> 30356352 |
Desmond Aroke1,2, Benjamin Momo Kadia3,4, Ephesians Nkwetta Anutebeh5, Cluade Asaba Belanquale6, Glory Masango Misori2,5, Alfred Awa7, Clarence M Mbanga8, Larry Tangie Ngek6.
Abstract
BACKGROUND: The endemic nature of the hepatitis B virus (HBV) in Sub-Saharan Africa is a significant public health problem that places health care providers (medical students inclusive) at increased risk of occupational exposure. However vaccination against HBV is not systematic among medical students in Cameroon. Thus, we sought to evaluate awareness and HBV vaccine coverage among medical students in Cameroon.Entities:
Mesh:
Substances:
Year: 2018 PMID: 30356352 PMCID: PMC6176293 DOI: 10.1155/2018/3673289
Source DB: PubMed Journal: Biomed Res Int Impact factor: 3.411
Definition of operational variables.
|
|
|
|---|---|
|
| |
| 8–12 of 12 correct responses | Good knowledge on signs and symptoms |
| 0–7 of 12 correct responses | Poor knowledge on signs and symptoms |
| 5–7 of 7 correct responses | Good knowledge on route of transmission |
| 0–4 of 7 correct responses | Poor knowledge on route of transmission |
|
| |
| ≥ 4 0f 7 Positive attitudes | Positive attitude towards HBV vaccine |
| ≥ 3 0f 6 Negative attitudes | Negative attitude towards HBV vaccine |
|
| |
| 3 | Complete vaccination |
| 1–2 | Incomplete vaccination |
| 0 | Not vaccinated |
HBV: Hepatitis B virus.
Sociodemographic characteristics of participants.
|
|
|
|
|---|---|---|
|
| ||
| Females | 384 | 53.93 |
| Single | 700 | 98.04 |
| FHS Buea (clinical year) | 390 (280) | 54.62 (39.22) |
| FHS Bamenda (clinical year) | 170 (90) | 23.81 (12.61) |
| FMBS Yaoundé I (clinical year) | 154 (78) | 21.67 (10.92) |
| Basic sciences | 266 | 37.18 |
| Clinical year | 448 | 62.82 |
N: Number of participants with the available information on the variable, FHS; Faculty of Health Sciences, FMBS; Faculty of Medicine and Biomedical Sciences.
Knowledge on hepatitis B virus infection and vaccine.
|
|
|
|
|
|---|---|---|---|
|
| |||
| HBV can be caused by bacteria (N=706) | 24 (3.40) | 674 (95.47) | 8 (1.13) |
| HBV is contagious (N=708) | 552 (77.97) | 138 (19.49) | 18 (2.54) |
| HBV carrier may look healthy without showing any symptoms of the disease (N=712) | 628 (88.20) | 46 (6.46) | 38 (5.34) |
| HBV can be lethal (N=712) | 670 (94.10) | 32 (4.49) | 10 (1.40) |
| Patients can spread HBV to health care workers (N=710) | 660 (92.96) | 34 (4.79) | 16 (2.25) |
| Health care workers can spread HBV to patients (N=704) | 630 (89.49) | 42 (5.97) | 32 (4.55) |
| HBV vaccination is not for all people (N=700) | 172 (24.57) | 482 (68.86) | 46 (6.57) |
| HBV vaccination does not cause hepatitis (N=700) | 456 (65.14) | 190 (27.14) | 54 (7.71) |
| HBV vaccination can prevent hepatitis (N=708) | 668 (94.35) | 30 (4.24) | 10 (1.41) |
| HBV vaccination does not increase the risk for complications (N=698) | 498 (71.35) | 106 (15.19) | 94 (13.47) |
| HBV vaccination is contraindicated in pregnancy (N=700) | 186 (16.57) | 240 (34.29) | 274 (39.14) |
| The HBV vaccine has 3 doses (N=694) | 474 (68.30) | 28 (4.03) | 192 (27.67) |
|
| |||
| Broken skin in contact with saliva contaminated with blood of HBV pos patient (N=706) | 636 (90.08) | 38 (5.38) | 32 (4.53) |
| Broken skin in contact with blood of HBV pos patients (N=710) | 650 (91.55) | 36 (5.07) | 24 (3.38) |
| Broken skin in contact with saliva of HBV pos patients (N=696) | 484 (69.54) | 138 (19.38) | 74 (10.63) |
| Intact skin with HBV pos patient (N=702) | 78 (11.11) | 562 (80.06) | 62 (8.83) |
| Intact skin with intact skin of HBV pos patient (N=704) | 86 (12.22) | 564 (80.11) | 54 (7.67) |
| Needle stick injury (N=698) | 584 (83.67) | 64 (9.17) | 50 (7.16) |
| Aerosol produced by a hand piece (N=688) | 94 (13.66) | 394 (57.27) | 200 (29.07) |
N: Number of participants with the available information on the variable, HBV: hepatitis B virus, pos: positive.
Positive and negative attitudes towards the hepatitis B vaccine.
|
|
|
|---|---|
|
| |
| I am at risk because of the nature of my work (N=690) | 608 (88.12) |
| Vaccination prevents spread of infection to patients (N=692) | 584 (84.39) |
| Vaccination protects my family members (N=698) | 634 (90.83) |
| Hepatitis B is a serious disease (N=698) | 678 (97.13) |
| Hepatitis vaccine is effective in preventing the disease (N=698) | 650 (93.12) |
| the vaccine is available at my work place (N=680) | 201 (29.41) |
| the risk of death among vaccinated persons is reduced compared to the non vaccinated (N=690) | 626 (90.72) |
|
| |
| I am worried about its adverse effects (N=690) | 338 (48.99) |
| I am afraid of infection (N=692) | 272 (39.31) |
| It is not effective in disease protection (N=686) | 66 (9.62) |
| I am not at high risk of contracting HBV (N=690) | 114 (16.52) |
| The vaccine is not available (N=688) | 110 (15.99) |
| I have limited contact with high risk persons (N=686) | 144 (22.45) |
N: Number of participants with the available information on the variable.